Ann: PTX-100 receives U.S. FDA Fast Track Designation, page-47

It’s heading in that direction, judging by the financial analysis at a conservative 10 % capture of market
if everything goes well in phase 2 we are looking very nice.

I had been hearing staggering figures thrown at me recently by fellow investors (friends) and just posted that I would love to see a financial analysis done on PTX and the potential.

Pretty amazing to think about, who would have thought Neuren Pharmaceuticals would get to their all time share price of I think it was $25.98 with 1 US licensing deal.

Let’s just hope we can get that sort of performance at market.